Related Experiment Video
Updated: Jul 26, 2026

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Antisense strategies to inhibit restenosis
1Columbia University College of Physicians & Surgeons, Department of Medicine, New York, NY 10032, USA.
Abstract:
Restenosis after percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting remains a major clinical problem. Vascular smooth muscle cell (SMC) proliferation and migration from the arterial wall media into the intima are believed to play a critical role in the pathogenesis of restenosis. Several studies have demonstrated that phosphorothioate (PS) oligodeoxynucleotides targeted against genes involved in SMC proliferation inhibit in vitro SMC proliferation and migration. Moreover, PS oligodeoxynucleotides targeted against the genes c-myb, c-myc, cdc2 kinase, cdk2 kinase, and proliferating cell nuclear antigen (PCNA) when delivered adventitially or intraluminally inhibit in vivo neointimal formation after balloon injury in both the rat carotid and porcine coronary artery models. The inhibitory effects of these PS oligodeoxynucleotides may be the result of their suppression of migration of medial SMC rather than suppression of medial or intimal cell proliferation. Other studies have demonstrated the presence of the potent guanosine or G-quartet aptameric inhibitory effect of the PS oligodeoxynucleotides. Experiments with cytidine homopolymers such as S-dC28, which lack guanosines, reveal the presence of potent non-G-quartet, non-sequence-specific inhibitory effects on in vitro SMC proliferation, migration, and adhesion as well as in vivo neointimal formation after rat carotid artery balloon injury. This is owing to the avid binding of these PS oligodeoxynucleotides to the SMC mitogens and chemoattractants platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF). The extent to which hybridization-dependent antisense, G-quartet aptameric, or non-G-quartet, non-sequence-specific inhibitory effects occurs is the result of PS oligodeoxynucleotide sequence, length, and concentration. The 18-mer guanosine-rich PS oligodeoxynucleotide ZK10 is a more potent in vitro SMC proliferation inhibitor than S-dC28, although both compounds manifest comparable in vivo inhibitory effects on neointimal formation in the rat carotid artery model of balloon injury. PS oligodeoxynucleotides also possess non-sequence-specific immunomodulatory effects, including the induction of interferon-gamma and the unmethylated CpG motif, which exhibits numerous immunomodulatory effects. Novel strategies to inhibit restenosis include the development of E2F transcription decoys that inhibit several cell cycle regulatory genes and diminish neointimal lesion formation. In addition, antisense oligonucleotides targeted against the anti-apoptotic gene bcl-xL, which when transfected into the vessel wall inhibits bcl-xl expression, induce a five-fold increase in apoptotic SMC intimal cells, and effect a marked attenuation of in vivo lesion dimensions, thereby suggesting frank vascular lesion regression.
Insights
Phosphorothioate oligodeoxynucleotides show promise in inhibiting vascular smooth muscle cell proliferation and migration, key factors in restenosis after coronary procedures. These compounds offer novel therapeutic strategies for preventing arterial narrowing and promoting vascular healing.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biotechnology
Background:
- Restenosis following percutaneous transluminal coronary angioplasty (PTCA) and stenting is a significant clinical challenge.
- Vascular smooth muscle cell (SMC) proliferation and migration are critical in restenosis pathogenesis.
- Phosphorothioate (PS) oligodeoxynucleotides have emerged as potential therapeutic agents.
Purpose of the Study:
- To investigate the efficacy of PS oligodeoxynucleotides in inhibiting SMC proliferation and migration.
- To explore the mechanisms underlying the inhibitory effects of PS oligodeoxynucleotides.
- To evaluate novel strategies for restenosis inhibition.
Main Methods:
- PS oligodeoxynucleotides targeting genes like c-myb, c-myc, cdc2 kinase, cdk2 kinase, and PCNA were used.
- In vitro studies assessed SMC proliferation, migration, and adhesion.
- In vivo studies utilized rat carotid and porcine coronary artery models of balloon injury.
- Experiments included cytidine homopolymers (S-dC28) and guanosine-rich oligodeoxynucleotides (ZK10).
- Novel strategies like E2F transcription decoys and antisense oligonucleotides against bcl-xL were explored.
Main Results:
- PS oligodeoxynucleotides targeting specific genes inhibited in vitro SMC proliferation and migration.
- Adventitial or intraluminal delivery of these PS oligodeoxynucleotides inhibited in vivo neointimal formation.
- Non-G-quartet, non-sequence-specific PS oligodeoxynucleotides (S-dC28) inhibited SMC functions by binding to PDGF and bFGF.
- ZK10 showed potent in vitro inhibition, with comparable in vivo effects to S-dC28.
- PS oligodeoxynucleotides exhibited non-sequence-specific immunomodulatory effects.
- E2F decoys and bcl-xL antisense oligonucleotides reduced neointimal lesion formation and promoted SMC apoptosis.
Conclusions:
- PS oligodeoxynucleotides effectively inhibit SMC proliferation, migration, and neointimal formation.
- Both sequence-dependent and non-sequence-specific mechanisms contribute to their inhibitory effects.
- Novel strategies targeting cell cycle regulation and apoptosis offer promising avenues for restenosis treatment.
- Further research into PS oligodeoxynucleotide properties and delivery methods is warranted.
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care

